|Podcasts|October 1, 2020
Episode 66: New Approach to Antithrombotics
Author(s)Elaine Quilici
Dr. Neil Hayward, CEO and founder of eXlthera, is here to discuss his company, which is developing Factor XI inhibitor antithrombotics that are attacking blood clots from a new angle and are giving patients new hope.
Advertisement
Dr. Neil Hayward, CEO and founder of eXlthera, is here to discuss his company, which is developing Factor XI inhibitor antithrombotics that are attacking blood clots from a new angle and are giving patients new hope.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Which Supply Chains are Most Exposed by Disruptions in The Strait of Hormuz?
2
Teva Enters $900 Million Agreement to Acquire Emalex
3
Pharmaceutical Risks in the Strait of Hormuz
4
Asembia ASX26: Adjusting Strategies to Adapt to an Uncertain Global Political and Regulatory Market
5